Liječnički vjesnik, Vol. 141 No. 7-8, 2019.
Pregledni rad
https://doi.org/10.26800/LV-141-7-8-29
Expression of micro RNAs (miRNAs) in myelodysplastic syndrome (MDS)
Mirjana Mariana Kardum Paro
; Klinički zavod za medicinsku biokemiju i laboratorijsku medicinu, Klinička bolnica Merkur, Zagreb; Sveučilišni centar za forenzične znanosti Sveučilišta u Splitu, Split
nga Mandac Rogulj
; Zavod za hematologiju, Klinika za unutarnje bolesti, Klinička bolnica Merkur, Zagreb
Gordana Kaić
; Zavod za kliničku citologiju i citogenetiku, Klinička bolnica Merkur, Zagreb
Biljana Jelić Puškarić
; Zavod za kliničku citologiju i citogenetiku, Klinička bolnica Merkur, Zagreb
Ika Kardum-Skelin
; Zavod za kliničku citologiju i citogenetiku, Klinička bolnica Merkur, Zagreb; Medicinski fakultet Sveučilišta u Zagrebu, Zagreb
Anita Škrtić
; Klinički zavod za patologiju i citologiju, Klinička bolnica Merkur, Zagreb;Medicinski fakultet Sveučilišta u Zagrebu, Zagreb
Slobodanka Ostojić Kolonić
; Zavod za hematologiju, Klinika za unutarnje bolesti, Klinička bolnica Merkur, Zagreb; Medicinski fakultet Sveučilišta u Zagrebu, Zagreb
Sažetak
Myelodisplasia or myelodysplastic syndrome (MDS) is the name for a group of heterogeneous clonal hematological disorders of hematopoietic stem cells followed by ineffective hematopoesis of one or more cell
lines and the emergence of consequent cytopenias with increased risk of progression to acute myelogenous leukemia (AML). Micro Messenger Ribonucleic Acids (miRNAs) are short, non-coding RNA molecules that, apart from contributing to MDS pathogenesis, act as regulators of epigenetic mechanisms and also are recognized as potential prognostic markers for early diagnosis and classification of MDS. The aim of the study was to examine the levels of gene expression of specific miRNAs (hsa-miR-125a, hsa-miR-99b, hsa-miR-126 and hsa-miR-125b) in healthy volunteers plasma and MDS diagnosed patients. Gene expressions of miRNAs were determined at the Clinical Institute of Medical Biochemistry and Laboratory Medicine, Merkur University Hospital, accredited according to EN ISO 15189:2012, in plasma samples of four healthy volunteers and 33 MDS patients diagnosed at the Institute of Hematology of the Clinic for Internal Diseases of Merkur University Hospital, Reference Center of the Ministry of Health of the Republic of Croatia for Diagnosis and Treatment of MDS. Statistically significant difference in gene expression of miRNA in healthy volunteers compared to the MDS patients was not found (P [hsa-miR- 125a] = 0.398; P [hsa-miR-99b] = 0.134; P [hsa- miR-126] = 0.305; P [hsa miR-125b] = 0.079). MiRNA ratios of hsa-miR-125a and hsa-miR-99b in MDS patients were almost twice as high compared to normalized levels of gene expression in healthy volunteers (2.30 versus 1.90), and the level of change of miRNAs hsa-miR-125 and hsa-miR-99b was more than two times higher than the level of change of miRNA hsa-miR-125b. Finally, the results of the research indicate that the gene expression of miRNAs hsa-miR-125a and hsa-miR-99b could be regulated by the same mechanism and could be clinically relevant in MDS patients.
Ključne riječi
MYELODYSPLASTIC SYNDROMES – blood, genetics, pathology; MicroRNAs – blood, genetics; HEMATOPOIESIS – genetics; REAL-TIME POLYMERASE CHAIN REACTION – methods; GENETIC EXPRESSION PROFILING; GENE EXPRESSION REGULATION; LEUKEMIA, MYELOID, ACUTE - genetics
Hrčak ID:
225769
URI
Datum izdavanja:
27.9.2019.
Posjeta: 2.311 *